Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Drug prices

  • News

Executive Summary

Average wholesale prices for the top 20 drugs prescribed in 1987 to persons under age 65 increased 82% between 1985 and 1991. The costs for top 20 drugs used by the elderly increased by an average of 79% during the same period, according to a study by Lewin-ICF that was released Sept. 10 by the advocacy organization Families USA. Greatest increases were for Norwich Eaton's decongestant/expectorant Entex LA (phenylpropanolamine HCl/guaifenesin), which increased 150% in price between 1986 and 1991. Wyeth-Ayerst's Premarin, Inderal (propranolol HCl) and Isordil (isosorbide dinitrate) rose 148%, 129% and 120%, respectively. PMA issued a same-day response noting that drugs account for .07 of the health dollar and pointing to moderating inflation as measured by the Producer Price Index.

Table

View full table

Tags:
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS021452

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By